Catherine Mealor

Christopher Marinac

Michael Rose

Russell Gunther

Stephen Scouten

- UCB announced **three- and four-year data** from open-label extension Phase 3 trials for **BIMZELX® (bimekizumab-bkzx)** in moderate-to-severe plaque psoriasis.  **[857855_20250917CL75527:0]** 
- The data showed that **48.9% of Week 16 PASI 0 responders sustained complete skin clearance (PASI 0)** at every study visit from Week 16 to four years.  **[857855_20250917CL75527:0]** 
- BIMZELX also demonstrated improvements in nail psoriasis, with **81.8% and 82.7% of patients achieving nail matrix and nail bed mNAPSI 0**, respectively, over three years.  **[857855_20250917CL75527:0]** 
- Among patients with psoriasis and four or more risk factors for PsA at baseline, **98.1% maintained PASE <47 (no PsA symptoms)** to three years, supporting long-term treatment to reduce PsA risk factors.  **[857855_20250917CL75527:0]**

UCB Announces Positive Long-Term Data for BIMZELX in Plaque Psoriasis

- UCB announced **three-year data** from the BE HEARD trials for **BIMZELX® (bimekizumab-bkzx)** in adults with moderate-to-severe hidradenitis suppurativa (HS) on **September 17, 2025**.  **[857855_20250917CL75509:0]** 
- The data demonstrated **sustained symptom relief**, with improvements in HiSCR75, HiSCR90, and HiSCR100 at one year sustained to three years in **81.2%**, **64.3%**, and **50.1%** of patients, respectively.  **[857855_20250917CL75509:0]** 
- **BIMZELX** continued to be **generally well tolerated**, with **no new safety signals observed up to three years**.  **[857855_20250917CL75509:0]** **[857855_20250917CL75509:1]** 
- Patients treated **earlier** in their moderate-to-severe HS with BIMZELX had **improved outcomes** at two years.  **[857855_20250917CL75509:0]**

UNITED COMMUNITY BANKS (UCB)